CIK 0001649989
- Non-accelerated filer
- Smaller reporting company
Outlook Therapeutics, Inc.
Sign in to watch- Ticker
- OTLK
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 383982704
- Phone
- +1 609-619-3990
- Business address
- 111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
- Former names
- Oncobiologics, Inc.
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3/A Insider 3/A
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Option exercise Director acquired 12,036 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award CFO and Secretary acquired 50,000 shares (grant or award)
- 3/A Insider 3/A
- 4 Grant or award SVP Bus. Strat. & Dev. acquired 30,000 shares (grant or award)
- 4 Grant or award VP, Regulatory Affairs acquired 45,000 shares (grant or award)
- 4 Grant or award SVP, Development & Mfrg acquired 40,000 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 50,000 shares (grant or award)
- 4 Grant or award VP, Analytical Sciences acquired 50,000 shares (grant or award)
- 4 Other acquisition Director acquired 1,939 shares (other)
Page 14 of 16 · 305 filings